1. Home
  2. Labeler Index
  3. State Of Florida Doh Central Pharmacy
  4. 53808-0616
  5. Product Images: Clopidogrel

Product Images Clopidogrel

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Clopidogrel NDC 53808-0616 by State Of Florida Doh Central Pharmacy, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 75 mg (30 Tablet Bottle) - CLOPIDOGREL

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 75 mg (30 Tablet Bottle) - CLOPIDOGREL

Figure 1: Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel Bisulfate 75 mg Alone or with Proton Pump Inhibitors (PPIs) - clopidogrel fig1

Figure 1: Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel Bisulfate 75 mg Alone or with Proton Pump Inhibitors (PPIs) - clopidogrel fig1

This is a graph (Figure 1) that shows the exposure to Clopidrogel Active Metabolite after taking multiple doses of Clopidrogel Bisulfate 75 mg alone or with Proton Pump Inhibitors (PPIs). The graph compares how different levels of PPI coadministration affects the active metabolite area under the curve (measured in mean and 90% confidence intervals). The graph shows the results for four different types of PPIs: Dexlansoprazole (60 mg), Lansoprazole (30 mg), Pantoprazole (80 mg), and Omeprazole (80 mg). The X-axis shows the different time points at which the measurements were taken, while the Y-axis shows the change in the active metabolite exposure relative to Clopidogrel Bisulfate administered alone.*

Figure 2: Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study - clopidogrel fig2

Figure 2: Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study - clopidogrel fig2

The text describes a figure titled "Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study". The figure shows the cumulative event rate in percentage for cardiovascular death, myocardial infarction, and stroke in patients who receive either a placebo (with aspirin) or clopidogrel bisulfate (with aspirin). The x-axis shows the months of follow-up. Other standard therapies were also used.*

Figure 3: Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study - clopidogrel fig3

Figure 3: Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study - clopidogrel fig3

Figure 4: Cumulative Event Rates for Death in the COMMIT Study* - clopidogrel fig4

Figure 4: Cumulative Event Rates for Death in the COMMIT Study* - clopidogrel fig4

This appears to be a table showing cumulative event rates for death in a study called "COMMIT" comparing a placebo to a drug called "Ciopidogret". The placebo group had 1,845 (6.1%) deaths and the Ciopidogret group had 1,726 (7.5%) deaths. There is also mention of proportional risk and reduction, as well as information about all treated patients receiving aspirin. It is unclear what the units or time frame are, as some of the numbers include non-readable characters.*

Figure 5: Cumulative Event Rates for the Combined Endpoint Re-Infarction, Stroke or Death in the COMMIT Study* - clopidogrel fig5

Figure 5: Cumulative Event Rates for the Combined Endpoint Re-Infarction, Stroke or Death in the COMMIT Study* - clopidogrel fig5

The text describes Figure 5 which shows the cumulative event rates for the combined endpoint of re-infarction, stroke, or death in the COMMIT study. The figure includes data on patients who received aspirin and either clopidogrel or placebo. The text also mentions that all treated patients received aspirin. There is additional information in the figure about the number of patients in each group and the days since randomization.*

Figure 6: Effects of Adding Clopidogrel Bisulfate to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study - clopidogrel fig6

Figure 6: Effects of Adding Clopidogrel Bisulfate to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study - clopidogrel fig6

This is a statistical analysis of the effects of adding Clopidogrel Bisulfate to aspirin on the combined primary endpoint of the COMMIT study. The analysis takes into account different baseline and concomitant medication subgroups. The data includes odds ratios and confidence intervals for baseline events, such as sex, age, and medication given. The global heterogeneity test was performed and reported in the study.*

Figure 7: Effects of Adding Clopidogrel Bisulfate to Aspirin in the Non-Prespecified Subgroups in the COMMIT Study - clopidogrel fig7

Figure 7: Effects of Adding Clopidogrel Bisulfate to Aspirin in the Non-Prespecified Subgroups in the COMMIT Study - clopidogrel fig7

Figure 8: Fatal or Non-Fatal Vascular Events in the CAPRIE Study - clopidogrel fig8

Figure 8: Fatal or Non-Fatal Vascular Events in the CAPRIE Study - clopidogrel fig8

Chemical Structure - clopidogrel str

Chemical Structure - clopidogrel str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.